

March, 2019

CURRICULUM VITAE

First name, surname Prof. Dr. Reinier O. Schlingemann
Gender Male
Date and place of birth 1-10-1960; Nijeveen
Nationality Dutch

Home address Rijksstraatweg 87
1396 JG Baambrugge
0294-291501
06-23727704

Present Positions

1. Professor of Ophthalmology and Medical Retina
Specialist
Department of Ophthalmology, Room A2-123.1
Amsterdam University Centers, location Academisch
Medisch Centrum
Meibergdreef 9
1105 AZ Amsterdam
+31205663682
r.schlingemann@amc.uva.nl

2. Director of Research and Invited Professor at the
University of Lausanne
Jules-Gonin Eye Hospital
Fondation Asile des Aveugles
Avenue de France 15
CP5143
1002 Lausanne
Switzerland
+41216268840
Reinier.schlingemann@fa2.ch

Secondary education

School Gymnasium, 1e Vrijzinnig Christelijk Lyceum, The Hague
Date June 20, 1979, Cum laude

Masters

University Medical School, University of Leiden, Leiden
Date January 25 1991, Cum laude
Main subject Medicine

Doctorate

University Nijmegen University, Nijmegen
Date December 17, 1990

Supervisor ('Promotor')	Prof. dr. D.J. Ruiter
Title of thesis	Vascular markers in tumor biology

Residency in Ophthalmology

University	Academic Medical Centre, University of Amsterdam, Amsterdam
Date	Oct 1 st , 1991- Oct 1 st 1995
Supervisor	Prof. dr. A.C. Breebaart

Medical retina fellowship

University	Moorfields Eye Hospital, University College London, London
Period	Dec 1995-Dec 1996
Supervisor	Prof. Alan C. Bird

Courses

1984	Course in Health Law, Law School, University of Leiden
1991	Course on Clinical Epidemiology, University of Amsterdam
1992	Course on Ophthalmic Standardized Echography by K.C. Ossoinig, Würzburg, Germany

Teaching qualification

Dec 2017	BKO: University Teaching Qualification (UTQ)
----------	--

Research and work positions

1981-1985	Student-assistant. Department of Pathology, University of Leiden (supervisor Professor Dr. D.J. Ruiter). Research subjects: angiogenesis, vascular biology and tumor vasculature. Subjects: 1) 'malignant melanoma and precursor lesions' 2) 'endothelial antigens'
1984	Student-assistant. Department of Medical Information Sciences, University of Leiden (supervisor Dr. N.J.I. Mars). Subject: 'Development of an Artificial Intelligence Expert System for the classification of colon biopsies'
1985-1986	Research assistant. Department of Pathology, University of Leiden. PhD program (Supervisor Prof. Dr. D.J. Ruiter, 14 months), 1.0 fte, fixed-term.
1986-1988	Cancer Research Campaign Fellowship. The Gray Laboratory, Northwood, England (supervisor Prof. Dr.J.Denekamp), and the Chester Beatty Laboratories and Royal Marsden Hospital, London (supervisor Prof. Dr. A.J.S.Davies, 12 months).
1987	Research Fellowship. The Thrombosis, Haematology Research Program of the Oklahoma Medical Research Foundation, Oklahoma, USA (protein biochemistry, supervisor Prof. Dr.D.M. Stern, 3 months).

1988-1989	Research assistant at the Department of Pathology, Nijmegen University. PhD program continued (supervisor Prof. Dr. D.J. Ruiter, 13 months), 1.0 fte, fixed-term.
1996	Senior Honorary Registrar, Moorfields Eye Hospital, London, UK (0.7 fte) and Research Fellowship, Institute of Ophthalmology, London, UK (0.3 fte, 12 months), fixed-term.
1997-present	Academisch medisch specialist (Medical specialist in Ophthalmology)
2008-present	Professor of Ophthalmology, with special focus on vascular disease of the macula, Ophthalmology, Amsterdam UMC, AMC, tenured term, now 0.45 fte
2018-present	Director of Research and Invited Professor at the University of Lausanne Jules-Gonin Eye Hospital ,, Fondation Asile des Aveugles, Lausanne, 0.5 fte

Management:

Ocular Clinical Trial Centre

-From 2000 Head of the Clinical Trial Bureau of the Dept. of Ophthalmology (principal) Investigator in the following trials- SECURE study, - RESTORE study, - RESTORE Extension study, BRAMD study, SOLVAY study, - BucTrial,, -RETAIN study, - EPRAS study, - BEGIN study, - BRVO study, - BRDME study, - PROMETHEUS study, etc.

Ocular Angiogenesis Group

-From 1995 founder and head of the Ocular Angiogenesis Group AMC, which included between 1.0 fte to 6.0 fte personnel and includes 3.0 fte at present. All funding of our group has been acquired by me from external sources. At present, the ocular angiogenesis group consists of:

Dr. Ingeborg Klaassen, Universitair Docent
 Ilse Vogels, Research technician

PhD Students

Drs. Bahar Arik
 Drs. M. Dallinga
 E. Bosma

Brief summary of research over last five years

In the last five years, my research group has investigated the pathobiological mechanisms underlying the two most important blinding diseases of the Western world: diabetic retinopathy (DR) and age-related macular degeneration (AMD). Because of my longstanding interest in endothelial cell biology, I chose in 1996 the sub-specialty of Medical Retina to focus specifically on these diseases, both as a clinician and as a researcher. Blindness in DR and AMD is caused by vascular leakage, angiogenesis and scarring. Therefore our translational research projects have focussed on the cellular and molecular mechanisms involved. Our work has profited from the valuable input of my clinical experience and my ability to set up collaborative projects with established investigators in basic sciences inside and outside the AMC (see publication list). Present collaborations are: Prof. Dr. C.J.F. van Noorden, Cell Biology and Histology AMC

(morphological and microscopical techniques, general advice), Dr. A.J. Horrevoets, Medical Biochemistry AMC (in vitro models of the blood-retinal barrier, gene transfection, comparative genomics/gene-expression studies), Dr. R.G. Goldschmeding, UMC (studies on CTGF, TGF- β s and pathology of the retina), and Prof. Dr. A.A.B. Bergen from the Netherlands Ophthalmic Research Institute, Amsterdam (comparative genomics/gene-expression studies, ocular disease models). Supported by this collaborative approach we have studied the following main subjects:

- Cellular and molecular basis of increased microvascular permeability in DR.
- Interactions between endothelial cells, leukocytes and platelets in DR as a cause of capillary loss in DR.
- Role of connective tissue growth factor (CTGF) in DR.
- Role of VEGF and its receptors in the healthy eye, ocular angiogenesis, and in DR.
- Pro-and anti-angiogenic functions of the retinal pigment epithelium in the pathogenesis of AMD.

These studies have led to several important contributions to the field:

- the discovery that polarized secretion of VEGF by epithelia maintains fenestrated capillaries in the normal eye and other tissues
- identification of retinal endothelial cell hypertrophy as a cause of vascular occlusion in DR
- the discovery that CTGF causes basement membrane thickening in PCDR and fibrosis in PDR.
- the discovery that altered vesicular transport via caveolae is an important mechanism of VEGF-induced retinal vascular leakage
- the discovery that the caveolar protein PLVAP is essential for retinal vascular leakage in macular edema

In addition, I have been involved in a series of more clinically oriented studies:

- Application of Orthogonal Polarization Spectral (OPS) imaging in ophthalmology
- Screening for diabetic retinopathy-Richtlijnenproject AMC.
- Clinical multi-centre trials employing anti-VEGF and anti-VEGF receptor strategies in patients with AMD and DR.

In the future I want to expand on the added value as a research-clinician, increase my expertise in state-of-the-art basic sciences, and help to unravel the causes of the diseases that are a burden for patients.

International collaborations

- Prof. dr. A.W. Stitt, Dr. T.A. Gardiner, Queen's University Belfast, Northern Ireland
- Prof. dr. H.-P. Hammes, University of Heidelberg, Germany
- Prof. dr. R. Simo, Vall d'Hebron Research Institute (VHIR), Spain

National collaborations

- Prof. Dr. C.J.F. van Noorden, Cell Biology and Histology, AMC.
- Prof. dr. A. Griffioen, MC Maastricht
- Prof. Dr. A.A.B. Bergen, Dept of Genetics, AMC
- Dr. R. Goldschmeding, University Medical Centre Utrecht
- Prof. Dr. S. Schulte-Merker, Hubrecht Institute, Utrecht

Scientific committees

2000-2005	Diabetes Fonds Nederland, Scientific Advisory Board
2001-present	Landelijke Stichting Blinden en Slechtzienden, Board member
1999-present	Medical Retina Working Group of the Netherlands Ophthalmological Society, co-founder; Chairman since 2011
2003-2007	Commissie Richtlijn Diabetische Retinopathie. Orde van Medisch Specialisten en Nederlandse Diabetes Federatie, Member
2009-present	Genootschap ter bevordering van Natuur-, Heel- en Geneeskunde. Founded 1790. Board member.
2012-present	Spinoza Committee of the Amsterdam University Fund. Official committee for hosting visiting professors at the Faculty of Medicine of the University of Amsterdam. Chairman.
2013-present	European Association for the Study of Diabetic Eye Disease (EASDEC). Board member and Secretary.
2000-2019	-Ad hoc referee for: Lancet, Laboratory Investigation, Diabetes, Diabetologia, Investigative Ophthalmology and Visual Science, Journal of Pathology, Acta Histochemica, Histology and Histopathology, Survey of Ophthalmology, Ophthalmic Research, Experimental Eye Research, Current Eye Research, Clinical and Experimental Ophthalmology -Ad hoc referee for international organisations for research funding: The Wellcome Trust UK, Deutsche Forschungsgemeinschaft, Fight for Sight UK, Health research Board of Ireland etc..

Editorial boards

2002-2005	Nederlands Tijdschrift voor Geneeskunde.
2003-2006	Graefe's Archive for Clinical and Experimental Ophthalmology.
2003-present	Nederlands Tijdschrift voor Diabetologie.
2007-2012	Framingham on Ophthalmology, selecting editor
2014-2019	Ophthalmic Research

(Co-)Promotor for PhD students

1996	Dr I. Mombaerts. Orbital pseudotumor.
2001	Dr. P. Hofman. Blood-ocular barriers in health and disease. Light and electron microscopic studies of the eye.
2002	Dr. A. Witmer. (Patho)physiological role of VEGFs in the eye.
2005	Dr. G. Misotten. Angiogenesis and screening in uveal melanoma.
2006	Dr. E.J. Kuiper. Role of connective tissue growth factor (CTGF) in diabetic retinopathy.
2010	Dr. J. Hughes. Endothelial dysfunction in experimental models of preclinical diabetic retinopathy.
2012	Drs. R. van Geest. Transforming Growth Factor-beta and Connective Tissue Growth Factor in Diabetic Retinopathy.
2013	Dr. M. Siemerink. Angiogenic tip cells in endothelial cell cultures.
2014	Dr. I. van der Meulen. Straylight in anterior segment disorders of the eye.
2014	Dr. P. Kok (Imaging groep Dr. F.D. Verbraak). Optical coherence tomography. Beware of optical illusions.

2014	Dr. J. Wisniewska. PLVAP in diabetic retinopathy. A gatekeeper of angiogenesis and vascular permeability.
2014	Drs. H. van Dijk. (Imaging groep Dr. F.D. Verbraak)
2018	Drs. N. Demirkaya (Imaging groep Dr. F.D. Verbraak. In Search of Retinal Biomarkers for HIV Related Neurodegeneration: The AGEhIV and NOVICE Studies.)
2018	Drs A-E van der Wijk. You build me up, you break me down: Molecular mechanisms of blood-retinal barrier development and disruption.
2018	Drs.E. Carvalho. Ophthalmic Molecular Imaging and the Role of the Proteasome in Retinal Diseases..

Expected

2019	Drs. M. Stehouwer (Imaging groep Dr. F.D. Verbraak)
2019	A.-S. Schauwvlieghe
2019	S. Darma (Imaging groep Dr. F.D. Verbraak)
2019	B. Arik-Yetkin
2019	Drs. M. Dallinga
2021	Dr. E. Bosma

Organization of courses, conferences and postgraduate education

2019	Organiser Annual meeting of EASDec, Amsterdam
2004-2014	Member, organizing committee of the two-yearly Amsterdam Retina Debate
2003	Member, organizing committee. Postgraduate education program in Ophthalmology for general practitioners
2002	Member, organizing committee. Fluorescein angiography. Postgraduate education for ophthalmologists. 14-12-2002, Zwolle
2002	Member, organizing committee. Age-related macular degeneration. Postgraduate education for ophthalmologists. 17-05-2002, Rotterdam
2001	Member, organizing committee. Age-related macular degeneration. Postgraduate education for ophthalmologists. 10-03-2001, Rotterdam
1999	Member, organizing committee. New developments in age-related macular degeneration. Postgraduate education for ophthalmologists. Nijmegen
1994	Member, organizing committee. 7 th SEOHS (Stichting Experimenteel Onderzoek Heelkundige Specialisten) meeting, Amsterdam.

Scholarships and prizes

Scholarship

1986-1988	Research Fellowship Grant from the Queen Wilhelmina Fonds (KWF)
-----------	---

Prizes

1986	Hippocrates Studiefonds Award, for excellent scientific work performed during Medical School.
1989	Poster prize. Annual meeting of the European Society for Pigment Cell Research, Venice, Italy.

- 1993 Nominated for the 1993 Pharmacia Research Grant for the Netherlands for an essay on "Quality of care: the use of anti-angiogenesis in oncology and ophthalmology".
- 1994 Poster prize. Annual meeting of the Netherlands Ophthalmological Society (NOG), The Hague.
- 1997 Best Abstract Award, 9th Endothelial Symposium, Rotterdam
- 2010 Netherlands Diabetes Fund Research Award: 50.000 euro and statue.

Major grants obtained as principal investigator (total approximately 3.700.000 euro)

- Euro 100 K PLVAP in the regulation of transcytosis in diabetic macular edema. Basic research project. 2019-2021. EASDF
- Euro 500 K 2018. Molecular mechanisms of PLVAP involvement in vascular permeability and its potential as therapeutic target for cerebral edema and diabetic macular edema. Basic research project anonymous fund. 2019-2023.
- Euro 25 K 2017. Cellular energy metabolism in angiogenic tip cells. *Funds of UitZicht*
- Euro 129 K 2016. Identification of circulating biomarkers as diagnostic markers in DME. *Funds of UitZicht*, Stichting Ooglijders en Rotterdamse Stichting Blindenbelangen
- Euro 246 K 2015. The tip cell as a target for anti-angiogenesis therapy in ocular retinopathies. Funds of UitZicht and other eye funds.
- Euro 146 K 2015. The developmental formation of the blood-retinal barrier as an inverse model of blood-retinal barrier loss in diseases of the retina. Basic research on the blood-retinal barrier in developing mouse retina. Funds of UitZicht
- Euro 250 K 2014. Defining the role of PLVAP in diabetic macular edema. *Diabetes Fonds Nederland (DFN) Grant 2014.00.1784*
- Euro 135 K 2014. BRB Development. *Funds of UitZicht*
- Euro 158 K 2013. Wat is de rol van IGF-2 in retinopathie of prematuriteit? *Funds of UitZicht and Rotterdamse Stichting Blindenbelangen*
- Euro 45 K 2013. VEGF-levels in plasma and platelets in patients with age-related macular degeneration, venous occlusions and diabetic retinopathy treated with anti-VEGF-agents. *Funds of UitZicht and Rotterdamse Stichting Blindenbelangen*
- Euro 170 K 2012. Application of an in vitro BRB model to explore molecular mechanisms and mode of action of current therapeutics in macular edema. *Rotterdamse Stichting Blindenbelangen, Stichting Blindenhulp, Stichting tot verbetering van het lot der blinden, Stichting voor Ooglijders, LSBS, MD Fonds, Stichting Blindenpenning*
- Euro 145 K 2012. Molecular regulation of angiogenic tip cells in neovascular age-related macular degeneration. *Rotterdamse Stichting Blindenbelangen, Stichting Blindenhulp, Stichting tot verbetering van het lot der blinden, Stichting voor Ooglijders, LSBS, MD Fonds, Stichting Blindenpenning*
- Euro 65 K 2011. The role of the angio-fibrotic switch in age-related macular degeneration *Rotterdamse Stichting Blindenbelangen, Stichting Blindenhulp, Stichting tot verbetering van het lot der blinden, Stichting voor Ooglijders, LSBS, MD Fonds, Stichting Blindenpenning*
- Euro 20 K 2011. Characterization of a mouse model of vascular permeability, retinal neovascularization and fibrosis. *Rotterdamse Stichting Blindenbelangen*
- Euro 106 K 2011. Mechanisms involved in neurite growth in epiretinal proliferations in proliferative diabetic retinopathy. *Rotterdamse Stichting Blindenbelangen, LSBS, Stichting voor Ooglijders, Stichting Nederlands Oogheelkundig Onderzoek*
- Euro 380 K 2011. Comparing the effectiveness and costs of bevacizumab to ranibizumab in patients with diabetic macular edema (The BRDME study) *Doelmatigheids Onderzoek ZonMw. (projectnummer 171202019)*

- Euro 380 K 2011. Comparing the effectiveness and costs of bevacizumab to ranibizumab in patients with retinal vein occlusion (The BRVO study)
Doelmatigheids Onderzoek ZonMw. (projectnummer 171202018)
- Euro 45 K 2010. CTGF pathway inhibition to prevent blindness from fibrosis in proliferative diabetic retinopathy. *Diabetes Fonds Nederland Grant 2010.11.1394*
- Euro 50 K 2010. *Diabetes Fonds Nederland (DFN) onderzoeksprijs*
- Euro 66 K 2009. The proteasome in the pathogenesis of age-related macular degeneration
St. Amphoraest
- Euro 65 K 2009. Identification of new targets for anti-angiogenesis therapy in age-related macular degeneration. *Landelijke Stichting Blinden en Slechtzienden, Stichting Blindenpenning, Rotterdamse Blindenvereniging, Stichting Blindenhulp.*
- Euro 140 K 2008. The role of transcellular microvascular leakage in diabetic retinopathy
Landelijke Stichting Blinden en Slechtzienden, Stichting Blindenpenning, Rotterdamse Blindenvereniging, Stichting Blindenhulp and others
- Euro 881 K 2007. Comparing the effectiveness and costs of bevacizumab and ranibizumab in patients with exudative age-related macular degeneration
Doelmatigheids Onderzoek ZonMw. (projectnummer 17088.5606)
- Euro 270 K 2005. The role of TGF- β s and BMPs in diabetic retinopathy.
Diabetes Fonds Nederland (DFN) Grant 2005.00.042
- Euro 73 K 2005. Possible role of angiopoietin-1 and -2 in angiogenesis and blood-retinal barrier loss in diabetic retinopathy. *Landelijke Stichting Blinden en Slechtzienden, Stichting Blindenpenning, Rotterdamse Blindenvereniging, Stichting Blindenhulp*
- Euro 81 K 2004. The role of advanced glycation end products in the induction of retinal endothelial apoptosis in diabetes. *Landelijke Stichting Blinden en Slechtzienden, Stichting Blindenpenning, Rotterdamse Blindenvereniging and Gelderse Blindenvereniging*
- Euro 85 K 2003. Application of Orthogonal Polarization Spectral (OPS) imaging in ophthalmology. *Landelijke Stichting Blinden en Slechtzienden, Stichting Blindenhulp.*
- Euro 56 K 2003. Pro- and anti-angiogenic functions of the Retinal Pigment Epithelium.
Landelijke Stichting Blinden en Slechtzienden, Stichting Blindenhulp and Stichting Blindenpenning
- Euro 45 K 2002. Screening for diabetic retinopathy-Richtlijnenproject AMC.
Richtlijnenproject AMC, co-applicant Prof.Dr. J.B.L. Hoekstra.
- Euro 240 K 2001. Role of connective tissue growth factor (CTGF) in the pathogenesis and treatment of diabetic retinopathy. *Diabetes Fonds Nederland (DFN) Grant 01.042.*
Co-applicant dr. R. Goldschmeding
- Euro 195 K 1999. Cellular and molecular basis of increased microvascular permeability in the retina and its role in the pathogenesis of diabetic retinopathy.
Diabetes Fonds Nederland (DFN) grant 1999.00.050
- Euro 200 K 1998. Interactions between endothelial cells, leukocytes and platelets in the pathogenesis of diabetic retinopathy. In vitro studies. *Diabetes Fonds Nederland (DFN) grant 1998.00.131*
- Euro 100 K 1998. Grant for 4 years for a research technician. *Landelijke Stichting Blinden en Slechtzienden*
- Euro 70 K 1997. Changes in the anterior segment in diabetes mellitus. *Rotterdamse Vereniging Blindenbelangen and Stichting Blindenpenning*
- Euro 195 K 1995. Characterisation of retinal microvascular permeability changes in relation to the pathogenesis of diabetic retinopathy.
Diabetes Fonds Nederland (DFN) grant 1995.00.103

Author of Guidelines

Commissie Richtlijn Diabetische Retinopathie. Orde van Medisch Specialisten en Nederlandse Diabetes Federatie (2003-2007)

Medische retina Werkgroep, Nederlands Oogheekundig Gezelschap: [Critical Appraisal Diabetic Macular Edema](#) (2013).

Medische retina Werkgroep, Nederlands Oogheekundig Gezelschap: [Critical Appraisal Retinal Venous Occlusions](#) (2013).

Netherlands Ophthalmological Society: [Richtlijn Leeftijdsgebonden Maculadegeneratie](#) (2016).

GCP training for clinical research:

- Profess ICH GCP Masterclass, December 1st 2009, Beurs van Berlage, Amsterdam. Certificate nr. 9122196
- View 2, certificate of attendance, 18-1-2008
- BROK: Basic course on Regulations and Organisation for clinical investigators, June 2016

Bibliometry

H-index: Web of Science All databases

56

Total citations:

9350

A handwritten signature in blue ink, appearing to be 'A. S.', is located at the bottom of the page.

Publications

-International (refereed) journals

Top publications

174. Dallinga MG, Yetkin-Arik B, Kayser RP, Vogels IMC, Nowak-Sliwinska P, Griffioen AW, van Noorden CJF, Klaassen I, Schlingemann RO.
IGF2 and IGF1R identified as novel tip cell genes in primary microvascular endothelial cell monolayers.
Angiogenesis. 2018 Nov;21(4):823-836 if 6.1
173. Van Bergen T, Etienne I, Cunningham F, Moons L, Schlingemann RO, Feyen JHM, Stitt AW.
The role of placental growth factor (PlGF) and its receptor system in retinal vascular diseases.
Prog Retin Eye Res. 2018 Oct 30. if 9.5
162. van der Wijk AE, Hughes JM, Klaassen I, Van Noorden CJF, **Schlingemann RO**.
Is leukostasis a crucial step or epiphenomenon in the pathogenesis of diabetic retinopathy?
J Leukoc Biol. 2017;102:993-1001. Review. if 4.0
171. Schauwvlieghe AM, Dijkman G, Hooymans JM, Verbraak FD, Hoyng CB, Dijkgraaf MG, Peto T, Vingerling JR, **Schlingemann RO**.
Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study.
PLoS One. 2016 May 20;11(5):e0153052. if 4.1
170. Sohn EH, van Dijk HW, Jiao C, Kok PH, Jeong W, Demirkaya N, Garmager A, Wit F, Kucukevcilioglu M, van Velthoven ME, DeVries JH, Mullins RF, Kuehn MH, **Schlingemann RO**, Sonka M, Verbraak FD, Abramoff MD. Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus.
Proc Natl Acad Sci U S A. 2016 May 10;113(19). if 9.7
169. Wisniewska-Kruk J, van der Wijk AE, van Veen HA, Gorgels TG, Vogels IM, Versteeg D, Van Noorden CJ, **Schlingemann RO**, Klaassen I.
Plasmalemma Vesicle-Associated Protein Has a Key Role in Blood-Retinal Barrier Loss.
Am J Pathol. 2016 Apr;186(4):1044-54. if 4.9

168. Klaassen I, Van Noorden CJ, **Schlingemann RO**. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions.
Prog Retin Eye Res. 2013 May;34:19-48. **if 9.5**
167. **R.O. Schlingemann**, C.J.F. van Noorden, M.J.M. Diekman, A. Tiller, J.C.M. Meijers, P. Koolwijk, and W.M. Wiersinga. VEGF levels in plasma in relation to platelet activation, glycemic control and microvascular complications in type I diabetes mellitus.
Diabetes Care 2013 Jan 15. [Epub ahead of print] **if 8.1**
166. Siemerink MJ, Klaassen I, Vogels IM, Griffioen AW, Van Noorden CJ, **Schlingemann RO**. CD34 marks angiogenic tip cells in human vascular endothelial cell cultures.
Angiogenesis. 2012 Mar;15(1):151-63. **if 6.1**
165. Kuiper EJ, Van Nieuwenhoven FA, de Smet MD, van Meurs JC, Tanck MW, Oliver N, Ingeborg Klaassen I, Van Noorden CJF, Goldschmeding R, **Schlingemann RO**.
The Angio-Fibrotic Switch of VEGF and CTGF in Proliferative Diabetic Retinopathy
PLoS ONE. 2008; 3:e2675 **if 4.1**
164. Hughes J.M., Kuiper E.J., Klaassen I., Canning P, Stitt A.W., Van Bezu J., Schalkwijk C.G., Van Noorden C.J.F., **R. O. Schlingemann**.
Advanced glycation end products cause increased CCN family and extracellular matrix gene expression in the diabetic rodent retina .
Diabetologia 2007; 50:1089-98. Epub 2007 Feb 28 **if 6.8**
163. E.J. Kuiper, M.D. de Smet, J.C. van Meurs, H.S. Tan, M.W.T. Tanck, N. Oliver, F.A. van Nieuwenhoven, R. Goldschmeding, **R.O. Schlingemann**.
Connective tissue growth factor is associated with fibrosis in vitreoretinal disorders in the human eye.
Archives of Ophthalmology 2006; 124:1457-62, **if 3.7**
162. B.-J.H. van den Born, C.A.A. Hulsman, J.B.L. Hoekstra, **R.O. Schlingemann**, G.A. van Montfrans.
Routine funduscopy to assess organ damage in patients with hypertension is not useful - a systematic review.
British Medical Journal 2005, 331: 73-76, **if 14.1**
161. G.B. Arden, W. Arap. R.L. Sidman, and **R.O. Schlingemann**
Spare the rod and spoil the eye. Perspective.
British Journal of Ophthalmology 2005, 89:764-769, **if 2.9**

160. **R.O. Schlingemann.**

Role of growth factors and the wound healing response in age-related macular degeneration. Review.

Graefe's Archive for Clinical and Experimental Ophthalmology 2004; 242: 91-10, **if 2.2**

159. VEGF Inhibition Study in Ocular Neovascularization **Clinical Trial Group.**

Pegaptanib for neovascular age-related macular degeneration.

New England Journal of Medicine 2004, 351: 2805-2816, **if 53.3**

158. S. Marchiò, J. Lahdenranta, **R.O. Schlingemann**, D. Valdembrì, P. Wesseling, M.A. Arap, A. Hajitou, M.G. Ozawa, M. Trepel, R.J. Giordano, D.M. Nanus, H.B.P. Dijkman, E. Oosterwijk, R.L. Sidman, M.D. Cooper, M. D., F. Bussolino, R. Pasqualini, and W. Arap.

Aminopeptidase A is a functional target in angiogenic blood vessels.

Cancer Cell 2004; 5: 151-162, **if 25.6**

157. A.N. Witmer, G.F.J.M. Vrensen, C.J.F. Van Noorden, and **R.O. Schlingemann.**

Vascular endothelial growth factors and angiogenesis in eye disease.

Progress in Retinal and Eye Research 2003; 22:1-29 **if 9.5**

156. A.N. Witmer, J. Dai, H.A. Weich, G.F.J.M. Vrensen, and **R.O. Schlingemann.**

Expression of vascular endothelial growth factor receptors 1, 2 and 3 in quiescent endothelia.

Journal of Histochemistry and Cytochemistry 2002; 50:767-777, **if 2.7**

155. J. Lahdenranta, R. Pasqualini, **R.O. Schlingemann**, M. Hagedorn, W.B. Stallcup, C. Bucana, R. Sidman, W. Arap.

An anti-angiogenic state in mice and humans with retinal photoreceptor cell degeneration.

Proceedings of the National Academy of Science USA 2001;98:10368-10373, **if 9.7**

154. P. Hofman, B.C. van Blijswijk, P.J. Gaillard, G.F.J.M. Vrensen, **R.O. Schlingemann.**

New insights into the pathogenesis of capillary non-perfusion in the retina: endothelial cell hypertrophy induced by vascular endothelial growth factor.

Archives of Ophthalmology 2001; 119:861-866, **if 3.7**

153. **R.O. Schlingemann**, P. Hofman, G.F.J.M. Vrensen and H.G.T. Blaauwgeers.

Increased expression of endothelial antigen PAL-E in human diabetic retinopathy correlates with microvascular leakage.

Diabetologia 1999; 42:596-602, **if 6.8**

152. H.G.T. Blaauwgeers, G.M. Holtkamp, H. Rutten, A.N. Witmer, T.A. Partanen, K. Alitalo, P.

Koolwijk, V.W.M. van Hinsbergh, M. Kroon, A. Kijlstra and **R.O. Schlingemann.**

Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of VEGF receptors on the inner choriocapillaris: evidence for a trophic paracrine relation.

American Journal of Pathology 1999;155:421-428, **if 4.9**

151. **R.O. Schlingemann**, A.A.J. Smit, H.F.E. Verduyn Lunel and A. Hijdra.

Amaurosis fugax on standing and angle closure glaucoma with clomipramine.

Lancet 1996; 347:465,

if 38.3

150. **R.O. Schlingemann**, F.J.R. Rietveld, R.M.W. de Waal and D.J. Ruiter.

Differential expression of markers for endothelial cells, pericytes and basal lamina in the microvasculature of tumors and granulation tissue.

American Journal of Pathology 1991; 138:1335-1347,

if 4.9

149. **R.O. Schlingemann**, F.J.R. Rietveld, R.M.W. de Waal, S. Ferrone and D.J. Ruiter.

Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds.

American Journal of Pathology 1990; 136:1393-1405

if 4.9

148. **R.O. Schlingemann**, F.J.R. Rietveld, R.M.W. de Waal, N.J. Bradley, A.I. Skene, A.J.S. Davies, M.F. Greaves, J. Denekamp and D.J. Ruiter.

Leukocyte antigen CD 34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stroma.

Laboratory Investigation 1990; 62:690-69,

if 3.6

147. **R.O. Schlingemann**, G.M. Dingjan, J.J. Emeis, J. Blok, S.O. Warnaar and D.J. Ruiter.

Monoclonal antibody PAL-E specific for endothelium.

Laboratory Investigation 1985; 52:71-75,

if 3.6

-Other publications in international (refereed) journals

146. Verbraak FD, Abramoff MD, Bausch GCF, Klaver C, Nijpels G, Schlingemann RO, van der Heijden AA. Diagnostic Accuracy of a Device for the Automated Detection of Diabetic Retinopathy in a Primary Care Setting.

Diabetes Care. 2019 Apr;42(4):651-656

145. van der Wijk AE, Wisniewska-Kruk J, Vogels IMC, van Veen HA, Ip WF, van der Wel NN, van Noorden CJF, Schlingemann RO, Klaassen I. Expression patterns of endothelial permeability pathways in the development of the blood-retinal barrier in mice.

FASEB J. 2019 Apr;33(4):5320-5333.

144. van Noort BC, Keunen JEE, Schlingemann RO, Marinkovic M. Long Survival and Preservation of Good Visual Acuity in a Patient with Bilateral Diffuse Uveal Melanocytic Proliferation.

Ocul Oncol Pathol. 2019 Jan;5(1):75-78. S1350-9462(18)30060-0.

143. Bosma EK, van Noorden CJF, Schlingemann RO, Klaassen I. The role of plasmalemma vesicle-associated protein in pathological breakdown of blood-brain and blood-retinal barriers: potential novel therapeutic target for cerebral edema and diabetic macular edema.

Fluids Barriers CNS. 2018 Sep 20;15(1):24.

142. van der Wijk AE, Canning P, van Heijningen RP, Vogels IMC, van Noorden CJF, Klaassen I, Schlingemann RO. Glucocorticoids exert differential effects on the endothelium in an in vitro model of the blood-retinal barrier.

Acta Ophthalmol. 2019 Mar;97(2):214-224. doi: 10.1111/aos.13909. Epub 2018 Aug 31

141. van der Wijk AE, Vogels IMC, van Veen HA, van Noorden CJF, Schlingemann RO, Klaassen I. Spatial and temporal recruitment of the neurovascular unit during development of the mouse blood-retinal barrier.

Tissue Cell. 2018 Jun;52:42-50.

140. Lorés-Motta L, Riaz M, Grunin M, Corominas J, van Asten F, Pauper M, Leenders M, Richardson AJ, Muether P, Cree AJ, Griffiths HL, Pham C, Belanger MC, Meester-Smoor MA, Ali M, Heid IM, Fritsche LG, Chakravarthy U, Gale R, McKibbin M, Inglehearn CF, Schlingemann RO, Omar A, Chen J, Koenekoop RK, Fauser S, Guymer RH, Hoyng CB, de Jong EK, Lotery AJ, Mitchell P, den Hollander AI, Baird PN, Chowers I. Association of Genetic Variants With Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration. JAMA Ophthalmol. 2018 Aug 1;136(8):875-884.

139. Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF, Bergers G, Bikfalvi A, Bischoff J, Böck BC, Brooks PC, Bussolino F, Cakir B, Carmeliet P, Castranova D, Cimpean AM, Cleaver O, Coukos G, Davis GE, De Palma M, Dimberg A, Dings RPM,

Djonov V, Dudley AC, Dufton NP, Fendt SM, Ferrara N, Fruttiger M, Fukumura D, Ghesquière B, Gong Y, Griffin RJ, Harris AL, Hughes CCW, Hultgren NW, Iruela-Arispe ML, Irving M, Jain RK, Kalluri R, Kalucka J, Kerbel RS, Kitajewski J, Klaassen I, Kleinmann HK, Koolwijk P, Kuczynski E, Kwak BR, Marien K, Melero-Martin JM, Munn LL, Nicosia RF, Noel A, Nurro J, Olsson AK, Petrova TV, Pietras K, Pili R, Pollard JW, Post MJ, Quax PHA, Rabinovich GA, Raica M, Randi AM, Ribatti D, Ruegg C, Schlingemann RO, Schulte-Merker S, Smith LEH, Song JW, Stacker SA, Stalin J, Stratman AN, Van de Velde M, van Hinsbergh VWM, Vermeulen PB, Waltenberger J, Weinstein BM, Xin H, Yetkin-Arik B, Yla-Herttuala S, Yoder MC, Griffioen AW. Consensus guidelines for the use and interpretation of angiogenesis assays.

Angiogenesis. 2018 Aug;21(3):425-532.

138. Ramos de Carvalho JE, Verwoert MT, Vogels IMC, Reits EA, Van Noorden CJF, Klaassen I, Schlingemann RO. Involvement of the ubiquitin-proteasome system in the expression of extracellular matrix genes in retinal pigment epithelial cells.

Biochem Biophys Res Commun. 2018 Jan 28;493:83-92.

137. Buitendijk GHS, Schauvlieghe AME, Vingerling JR, Schlingemann RO, Klaver CCW; comparing Bevacizumab to Ranibizumab in Age-related macular degeneration (BRAMD) Trial Research Group. Antiplatelet and Anticoagulant Drugs Do Not Affect Visual Outcome in Neovascular Age-Related Macular Degeneration in the BRAMD Trial.

Am J Ophthalmol. 2018 Mar;187:130-137.

136. Klaassen I, de Vries EW, Vogels IMC, van Kampen AHC, Bosscha MI, Steel DHW, Van Noorden CJF, Lesnik-Oberstein SY, **Schlingemann RO**. Identification of proteins associated with clinical and pathological features of proliferative diabetic retinopathy in vitreous and fibrovascular membranes.

PLoS One. 2017 Nov;12(11)

135. Ramos de Carvalho JE, Verwoert MT, Vogels IMC, Schipper-Krom S, Van Noorden CJF, Reits EA, Klaassen I, **Schlingemann RO**. Modulation of the Proteasome Pathway

by Nano-Curcumin and Curcumin in Retinal Pigment Epithelial Cells.

Ophthalmic Res. 2017 Oct 27. doi: 10.1159/000481261. [Epub ahead of print]

134. Hendriks M, Verhoeven VJM, Buitendijk GHS, Polling JR, Meester-Smoor MA, Hofman A; **RD5000 Consortium**, Kamermans M, Ingeborgh van den Born L, Klaver CCW.

Development of refractive errors - what can we learn from inherited retinal dystrophies?

Am J Ophthalmol. 2017 Oct;182:81-89.

133. Bennis A, Jacobs JG, Catsburg LAE, Ten Brink JB, Koster C, Schlingemann RO, van Meurs J, Gorgels TGME, Moerland PD, Heine VM, Bergen AA. Stem Cell Derived Retinal Pigment Epithelium: The Role of Pigmentation as Maturation Marker and Gene Expression Profile Comparison with Human Endogenous Retinal Pigment Epithelium.

Stem Cell Rev. 2017 Jul 21. [Epub ahead of print]

132. van der Wijk AE, Vogels IMC, van Noorden CJF, Klaassen I, **Schlingemann RO**. TNF α -Induced Disruption of the Blood-Retinal Barrier In Vitro Is Regulated by Intracellular 3',5'-Cyclic Adenosine Monophosphate Levels.

Invest Ophthalmol Vis Sci. 2017 Jul 1;58(9):3496-3505.

131: Fickweiler W, Schauwvlieghe AM, **Schlingemann RO**, Maria Hooymans JM, Los LI, Verbraak FD; BRDME Research Group. Predictive value of optical coherence

Tomographic features in the bevacizumab and ranibizumab in patients with diabetic macular edema (BRDME) study.

Retina. 2018 Apr;38(4):812-819

130. Ramos de Carvalho JE, **Schlingemann RO**, Oranje M, Bemelman FJ, van Schooneveld

MJ. Reversal of threatening blindness after initiation of eculizumab in Purtscher-like retinopathy secondary to atypical hemolytic uremic syndrome.

Int Ophthalmol. 2018 Feb;38(1):399-407.

129. Chung WH, van Dijk EH, Mohabati D, Dijkman G, Yzer S, de Jong EK, Fauser S,

Schlingemann RO, Hoyng CB, Boon CJ. Neovascular age-related macular degeneration

without drusen in the fellow eye: clinical spectrum and therapeutic outcome.

Clin Ophthalmol. 2016 Dec 21;11:63-70.

128. Bittner M, Faes L, Boehni SC, Bachmann LM, **Schlingemann RO**, Schmid MK. Colour Doppler analysis of ophthalmic vessels in the diagnosis of carotid artery and retinal vein occlusion, diabetic retinopathy and glaucoma: systematic review of test accuracy studies.

BMC Ophthalmol. 2016 Dec 7;16(1):214. Review.

127. Fickweiler W, Klaassen I, Vogels IM, Hooymans JM, Wolffenbuttel BH, Los LI, **Schlingemann RO**; BRDME Research Group. Association of Circulating Markers With Outcome Parameters in the Bevacizumab and Ranibizumab in Diabetic Macular Edema Trial.

Invest Ophthalmol Vis Sci. 2016 Nov 1;57(14):6234-6241.

126. Palm MM, Dallinga MG, van Dijk E, Klaassen I, **Schlingemann RO**, Merks RM. Computational Screening of Tip and Stalk Cell Behavior Proposes a Role for Apelin Signaling in Sprout Progression.

PLoS One. 2016 Nov 9;11(11)

125. Siemerink MJ, Hughes MR, Dallinga MG, Gora T, Cait J, Vogels IM, Yetin-Arik B, Van Noorden CJ, Klaassen I, McNagny KM, **Schlingemann RO**. CD34 Promotes Pathological Epi-Retinal Neovascularization in a Mouse Model of Oxygen-Induced Retinopathy.

PLoS One. 2016 Jun 28;11(6): Erratum in: *PLoS One.* 2016 Dec 21;11(12)

124. Lapid-Gortzak R, Traversari R, van der Linden JW, Lesnik Oberstein SY, Lapid O, **Schlingemann RO**. Mobile ultra-clean unidirectional airflow screen reduces air contamination in a simulated setting for intra-vitreous injection. *Int Ophthalmol.* 2017 Feb;37(1):131-137.

123. Demirkaya N, Wit FW, van Den Berg TJ, Kooij KW, Prins M, **Schlingemann RO**, Abramoff MD, Reiss P, Verbraak FD; AGEhIV Cohort Study Group. HIV-Associated Neuroretinal Disorder in Patients With Well-Suppressed HIV-Infection: A Comparative Cohort Study.

Invest Ophthalmol Vis Sci. 2016 Mar;57(3):1388-97.

122. Wisniewska-Kruk J, van der Wijk AE, van Veen HA, Gorgels TG, Vogels IM,

Versteeg D, Van Noorden CJ, **Schlingemann RO**, Klaassen I. Plasmalemma

Vesicle-Associated Protein Has a Key Role in Blood-Retinal Barrier Loss.

Am J Pathol. 2016 Apr;186(4):1044-54.

121. Ribeiro L, Bandello F, Tejerina AN, Vujosevic S, Varano M, Egan C, Sivaprasad S, Menon G, Massin P, Verbraak FD, Lund-Andersen H, Martinez JP, Jürgens I, Smets E, Coriat C, Wiedemann P, Ágoas V, Querques G, Holz FG, Nunes S, Neves C, Cunha-Vaz J; **Evicr Net Study Group**. Characterization of Retinal Disease

Progression in a 1-Year Longitudinal Study of Eyes With Mild Nonproliferative Retinopathy in Diabetes Type 2.

Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5698-705.

120. Stehouwer M, Verbraak FD, **Schlingemann RO**, van Leeuwen TG.

Detecting signs of retinal leakage in exudative AMD using Cirrus OCT versus SL SCAN-1, a novel integrated FD-OCT into a common slit lamp.

Graefes Arch Clin Exp Ophthalmol. 2016 Jan;254(1):37-41.

119. Demirkaya N, Wit F, Schlingemann RO, Verbraak F.

Neuroretinal Degeneration in HIV Patients Without Opportunistic Ocular Infections in the cART Era.

AIDS Patient Care STDS. 2015 Oct;29(10):519-32.

118. Weiss A, Ding X, van Beijnum JR, Wong I, Wong TJ, Berndsen RH, Dormond O, Dallinga

M, Shen L, **Schlingemann RO**, Pili R, Ho CM, Dyson PJ, van den Bergh H, Griffioen AW, Nowak-Sliwinska P.

Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer.

Angiogenesis. 2015 Jul;18(3):233-44.

117. Schauwvlieghe AM, Dijkman G, Hooymans JM, Verbraak FD, Hoyng CB, Dijkgraaf MG,

Van Leeuwen R, Vingerling JR, Moll AC, Schlingemann RO.

Comparing the effectiveness and costs of Bevacizumab to Ranibizumab in patients with Diabetic Macular Edema: a randomized clinical trial (the BRDME study).

BMC Ophthalmol. 2015 Jul 7;15:71.

116. Demirkaya N, Cohen S, Wit FW, Abramoff MD, Schlingemann RO, Kuijpers TW, Reiss P,

Pajkrt D, Verbraak FD.

Retinal Structure and Function in Perinatally HIV-Infected and cART-Treated Children: A Matched Case-Control Study.

Invest Ophthalmol Vis Sci. 2015 Jun;56(6):3945-54.

115. Klaassen I, van Geest RJ, Kuiper EJ, van Noorden CJ, **Schlingemann RO**.

The role of CTGF in diabetic retinopathy.

Exp Eye Res. 2015 Apr;133:37-48.

114. Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, **Schlingemann R.O**, Eldem B, Monés J, Richard G, Bandello F; European Society of Retina Specialists..

Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).

Br J Ophthalmol. 2014 Sep;98(9):1144-67.

113. Demirkaya N, Wit FW, van Den Berg TJ, Kooij KW, Prins M, **Schlingemann RO**, Abramoff MD, Reiss P, Verbraak FD; AGEhIV Cohort Study Group..HIV-Associated Neuroretinal Disorder in Patients With Well-Suppressed HIV-Infection: A Comparative Cohort Study.

Invest Ophthalmol Vis Sci. 2016 Mar;57(3):1388-97.

112. Lapid-Gortzak R, Traversari R, van der Linden JW, Lesnik Oberstein SY, Lapid O, **Schlingemann RO**.

Mobile ultra-clean unidirectional airflow screen reduces air contamination in a simulated setting for intra-vitreous injection.

Int Ophthalmol. 2016 Apr 30.

111. Siemerink MJ, Hughes MR, Dallinga MG, Gora T, Cait J, Vogels IM, Yetin-Arik B, Van Noorden CJ, Klaassen I, McNagny KM, **Schlingemann RO**.

CD34 Promotes Pathological Epi-Retinal Neovascularization in a Mouse Model of Oxygen-Induced Retinopathy.

PLoS One. 2016 Jun 28;. doi: 10.1371

110. van Huet RA, Oomen CJ, Plomp AS, van Genderen MM, Klevering BJ, **Schlingemann**

RO, Klaver CC, van den Born LI, Cremers FP; RD5000 Study Group. The RD5000

Database: Facilitating Clinical, Genetic, and Therapeutic Studies on Inherited

Retinal Diseases.

Invest Ophthalmol Vis Sci. 2014 Nov 17;55(11):7355-60.

109. Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, **Schlingemann R**,

Eldem B, Monés J, Richard G, Bandello F; European Society of Retina Specialists.

Guidelines for the management of neovascular age-related macular degeneration by

the European Society of Retina Specialists (EURETINA).

Br J Ophthalmol. 2014 Sep;98(9):1144-67.

- 108 . Noort AR, van Zoest KP, Weijers EM, Koolwijk P, Maracle CX, Novack DV, Siemerink MJ, **Schlingemann RO**, Tak PP, Tas SW. NF- κ B-inducing kinase is a key regulator of inflammation-induced and tumour-associated angiogenesis.
J Pathol. 2014 Nov;234(3):375-85.
- 107 . Boyer DS, Goldbaum M, Leys AM, Starita C; **V.I.S.I.O.N. Study Group**; V I S I O N Study Group. Effect of pegaptanib sodium 0.3 mg intravitreal injections (Macugen) in intraocular pressure: posthoc analysis from V.I.S.I.O.N. study.
Br J Ophthalmol. 2014 Nov;98(11):1543-6.
- 106 . Wisniewska-Kruk J, Klaassen I, Vogels IM, Magno AL, Lai CM, Van Noorden CJ, **Schlingemann RO**, Rakoczy EP. Molecular analysis of blood-retinal barrier loss in the Akimba mouse, a model of advanced diabetic retinopathy.
Exp Eye Res. 2014 May;122:123-31.
- 105 . van Zijderveld R, Ince C, Schlingemann RO. Orthogonal polarization spectral imaging of conjunctival microcirculation.
Graefes Arch Clin Exp Ophthalmol. 2014 May;252(5):773-9.
104. Ramos de Carvalho JE, Verbraak FD, Aalders MC, van Noorden CJ, Schlingemann RO. Recent advances in ophthalmic molecular imaging. *Surv Ophthalmol.* 2014 Jul-Aug;59(4):393-413.
- 103 Schmidt-Erfurth U, Lang GE, Holz FG, **Schlingemann RO**, Lanzetta P, Massin P, Gerstner O, Bouazza AS, Shen H, Osborne A, Mitchell P; RESTORE Extension Study Group. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study.
Ophthalmology. 2014 May;121(5):1045-53.
- 102 Van Geest RJ, Leeuwis JW, Dendooven A, Pfister F, Bosch K, Hoeben KA, Vogels IM, Van der Giezen DM, Dietrich N, Hammes HP, Goldschmeding R, Klaassen I, Van Noorden CJ, **Schlingemann RO**. Connective tissue growth factor is involved in structural retinal vascular changes in long-term experimental diabetes.

J Histochem Cytochem. 2014 Feb;62(2):109-18.

- 101 Ramos de Carvalho JE, Klaassen I, Vogels IM, Schipper-Krom S, van Noorden CJ, Reits E, Gorgels TG, Bergen AA, **Schlingemann RO**. Complement factor C3a alters proteasome function in human RPE cells and in an animal model of age-related RPE degeneration.

Invest Ophthalmol Vis Sci. 2013 Oct 3;54(10):6489-501.

- 100 Mitchell P, Bressler N, Tolley K, Gallagher M, Petrillo J, Ferreira A, Wood R, Bandello F; **RESTORE Study Group**. Patient-reported visual function outcomes Improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial.

JAMA Ophthalmol. 2013 Oct;131(10):1339-47.

99. Kok PH, van Dijk HW, Stehouwer M, van den Berg TJ, **Schlingemann RO**, Verbraak FD. Standardised disturbance of the optical coherence tomography signal has varying effects on the scan quality assessment when comparing four devices.

Br J Ophthalmol. 2013 Nov;97(11):1484-5.

98. Demirkaya N, van Dijk HW, van Schuppen SM, Abramoff MD, Garvin MK, Sonka M, **Schlingemann RO**, Verbraak FD. Effect of age on individual retinal layer thickness in normal eyes as measured with spectral-domain optical coherence tomography.

Invest Ophthalmol Vis Sci. 2013 Jul 22;54(7).

97. Lang GE, Berta A, Eldem BM, Simader C, Sharp D, Holz FG, Sutter F, Gerstner O, Mitchell P; **RESTORE Extension Study Group**. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study.

Ophthalmology. 2013 Oct;120(10):2004-12.

96. Pennock S, Kim D, Mukai S, Kuhnle M, Chun DW, Matsubara J, Cui J, Ma P, Maberley D, Samad A, Van Geest RJ, Oberstein SL, **Schlingemann RO**, Kazlauskas A. Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a onangiogenic blinding disease.

Am J Pathol. 2013 May;182(5):1659-70.

95. Silva R, Axer-Siegel R, Eldem B, Guymer R, Kirchhof B, Papp A, Seres A, Gekkieva M, Nieweg A, Pilz S; **SECURE Study Group**. The SECURE Study: Long-Term Safety of Ranibizumab 0.5 mg in Neovascular Age-related Macular Degeneration.
Ophthalmology. 2013 Jan;120(1):130-9. Epub 2012 Sep 25. **if 5.5**
94. Falke LL, Dendooven A, Leeuwis JW, Nguyen TQ, van Geest RJ, van der Giezen DM, Broekhuizen R, Lyons K, Stoop R, Kemperman H, **Schlingemann R**, Joles JA, Goldschmeding R. Hemizygous deletion of CTGF/CCN2 does not suffice to prevent fibrosis of the severely injured kidney.
Matrix Biol. 2012 Sep;31(7-8):421-31. **if 3.3**
93. Dell'omo R, Tan HS, **Schlingemann RO**, Bijl HM, Lesnik Oberstein SY, Barca F, Mura M. Evolution of outer retinal folds occurring after vitrectomy for retinal detachment repair.
Invest Ophthalmol Vis Sci. 2012 Dec 3;53(13):7928-35. **if 3.6**
92. Van Geest RJ, Klaassen I, Lesnik-Oberstein SY, Tan HS, Mura M, Goldschmeding R, Van Noorden CJ, **Schlingemann RO**.
Vitreous TIMP-1 levels associate with neovascularization and TGF- β 2 levels but not with fibrosis in the clinical course of proliferative diabetic retinopathy.
J Cell Commun Signal. 2012 Oct 2. **if 3.4**
91. Siemerink MJ, Klaassen I, Van Noorden CJ, **Schlingemann RO**. Endothelial Tip Cells in Ocular Angiogenesis: Potential Target for Anti-angiogenesis Therapy.
J Histochem Cytochem. 2012 Oct 23. [Epub] **if 2.7**
90. Van Dijk HW, Verbraak FD, Kok PH, Oberstein SY, **Schlingemann RO**, Russell SR, Abramoff MD. Variability in photocoagulation treatment of diabetic macular oedema. *Acta Ophthalmol*. 2012 Sep 13. **if 2.6**
89. Van der Meulen IJ, Gjertsen J, Kruijt B, Witmer JP, Rulo A, **Schlingemann RO**, van den Berg TJ. Straylight measurements as an indication for cataract surgery.
J Cataract Refract Surg. 2012; 38(5):840-8 **if 2,3**
88. Van Dijk HW, Verbraak FD, Kok PH, Stehouwer M, Garvin MK, Sonka M, Devries JH, **Schlingemann RO**, Abramoff MD. Early neurodegeneration in the retina of type 2 diabetic patients.
Invest Ophthalmol Vis Sci. 2012; 53(6):2715-9. 2012 **if 3.6**

87. Van Geest RJ, Lesnik-Oberstein SY, Tan HS, Mura M, Goldschmeding R, Van Noorden CJ, Klaassen I, **Schlingemann RO**. A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy.
Br J Ophthalmol. 2012; 96(4):587-90. **if 2.9**
86. Bandello F, Cunha-Vaz J, Chong NV, Lang GE, Massin P, Mitchell P, Porta M, Prunte C, **Schlingemann R**, Schmidt-Erfurth U. New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel.
Eye (Lond). 2012; 26(4):485-93 **if 1.9**
85. Wisniewska-Kruk J, Hoeben KA, Vogels IM, Gaillard PJ, Van Noorden CJ, **Schlingemann RO**, Klaassen I. [A novel co-culture model of the blood-retinal barrier based on primary retinal endothelial cells, pericytes and astrocytes.](#)
Exp Eye Res. 2012; 96(1):181-90. **if 3.3**
84. Berner AK, Brouwers O, Pringle R, Klaassen I, Colhoun L, McVicar C, Brockbank S, Curry JW, Miyata T, Brownlee M, **Schlingemann RO**, Schalkwijk C, Stitt AW.
Protection against methylglyoxal-derived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and vasodegenerative pathology.
Diabetologia. 2012; 55(3):845-54 **if 6.8**
83. Reuwer AQ, Sondermeijer BM, Battjes S, van Zijderveld R, Stuijver DJ, Bisschop PH, Twickler MT, Meijers JC, **Schlingemann RO**, Stroes ES. Microcirculation and atherothrombotic parameters in prolactinoma patients: a pilot study.
Pituitary. 2012; 15(4):472-81 **if 1.8**
82. Gorgels TG, Waarsing JH, Herfs M, Versteeg D, Schoensiegel F, Sato T, **Schlingemann RO**, Ivandic B, Vermeer C, Schurgers LJ, Bergen AA. Vitamin K supplementation increases vitamin K tissue levels but fails to counteract ectopic calcification in a mouse model for pseudoxanthoma elasticum.
Journal of Molecular Medicine. 2011;89:1125-35 **if 4.7**
81. Niers TM, Richel DJ, Meijers JC, **Schlingemann RO**. Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker.
PLoS One. 2011;6(5):e19873. *Epub 2011 May 26.* **if 4.1**
80. Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, **Schlingemann RO**, Weichselberger A, Staurenghi G; SUSTAIN Study Group. Safety and Efficacy of a

- Flexible Dosing Regimen of Ranibizumab in Neovascular Age-Related Macular Degeneration: The SUSTAIN Study.
Ophthalmology. 2011; 118: 663-71. if 5.5
79. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, **Schlingemann RO**, Sutter F, Simader C, Burian G, Gerstner O, Weichselberger A; RESTORE study group. The RESTORE Study Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy for Diabetic Macular Edema.
Ophthalmology. 2011; 118: 615-25. if 5.5
78. Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, **Schlingemann RO**, Axer-Siegel R, Wiedemann P, Simader C, Gekkieva M, Weichselberger A; EXCITE Study Group. Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration The *EXCITE Study*.
Ophthalmology. 2011 118(5):831-9. Epub 2010 Dec 13. if 5.5
77. Hughes JM, Groot AJ, van der Groep P, Sersansie R, Vooijs M, van Diest PJ, Van Noorden CJ, **Schlingemann RO**, Klaassen I. Active HIF-1 in the normal human retina.
J Histochem Cytochem. 2010 Mar;58(3):247-54. Epub 2009 Nov 9. if 2.7
76. Broekhuizen LN, Lemkes BA, Mooij HL, Meuwese MC, Verberne H, Holleman F, **Schlingemann RO**, Nieuwdorp M, Stroes ES, Vink H. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. *Diabetologia*. 2010 53(12):2646-55. Epub 2010 Sep 25. if 6.8
75. van Dijk HW, Verbraak FD, Stehouwer M, Kok PH, Garvin MK, Sonka M, Devries JH, **Schlingemann RO**, Abramoff MD. Association of visual function and ganglion cell layer thickness in patients with diabetes mellitus type 1 and no or minimal diabetic retinopathy.
Vision Res. 2011; 51(2):224-8. Epub 2010 Aug 27 if 2.4
74. Missotten GS, **Schlingemann RO**, Jager MJ. Angiogenesis and vascular endothelial growth factors in intraocular tumors.
Dev Ophthalmol. 2010;46:123-32. Epub 2010 Aug 10..
73. Siemerink MJ, Augustin AJ, **Schlingemann RO**. Mechanisms of ocular angiogenesis

and its molecular mediators.

Dev Ophthalmol. 2010;46:4-20. Epub 2010 Aug 10.

72. van der Meulen IJ, Engelbrecht LA, van Vliet JM, Lapid-Gortzak R, Nieuwendaal CP, Mourits MP, **Schlingemann RO**, van den Berg TJ. Straylight measurements in contact lens wear.
- Cornea.* 2010; 29:516-22. PubMed PMID: 20299974. **if 1.7**
71. van Dijk HW, Verbraak FD, Kok PH, Garvin MK, Sonka M, Lee K, Devries JH, Michels RP, van Velthoven ME, **Schlingemann RO**, Abramoff MD. Decreased retinal ganglion cell layer thickness in patients with type 1 diabetes.
- Invest Ophthalmol Vis Sci.* 2010; 51:3660-5. Epub 2010 Feb 3. **if 3.6**
70. Van Geest RJ, Klaassen I, Vogels IM, Van Noorden CJ, **Schlingemann RO**. Differential TGF- β signaling in retinal vascular cells: a role in diabetic retinopathy?
- Invest Ophthalmol Vis Sci.* 2010 51:1857-65. Epub 2009 Dec 3.. **if 3.6**
69. Van Dijk HW, Kok PH, Garvin M, Sonka M, Devries JH, Michels RP, van Velthoven ME, **Schlingemann RO**, Verbraak FD, Abramoff MD.
- Selective Loss of Inner Retinal Layer Thickness in Type 1 Diabetic Patients with Minimal Diabetic Retinopathy.
- Investigative Ophthalmology and Visual Science* 2009; 50:3404-9. **if 3.6**
68. **Schlingemann RO**, Witmer AN. Treatment of retinal diseases with VEGF antagonists.
- Prog. Brain Res.* 2009;175:253-67. Review.
67. Klaassen I, Hughes JM, Vogels I, Schalkwijk, CG, Van Noorden CJ, **Schlingemann, RO**.
- Altered Expression of Genes Related to Blood-Retina Barrier Disruption in Streptozotocin-Induced Diabetes
- Experimental Eye Research* 2009, jun: 15;89(1):4-15
66. [Kuiper EJ](#), [Hughes JM](#), [Van Geest RJ](#), [Vogels IM](#), [Goldschmeding R](#), [Van Noorden CJ](#), [Schlingemann RO](#), [Klaassen I](#).
- Effect of VEGF-A on expression of profibrotic growth factor and extracellular matrix genes in the retina.
- Investigative Ophthalmology and Visual Science* 2007; 48:4267-76,
65. [Kuiper EJ](#), [Roestenberg P](#), [Ehlken C](#), [Lambert V](#), [Bloys van Treslong-de Groot H](#), [Lyons KM](#), [Agostini HJ](#), [Rakic JM](#), [Klaassen I](#), [Van Noorden CJ](#), [Goldschmeding R](#), [Schlingemann RO](#).

Angiogenesis is not impaired in Connective Tissue Growth Factor (CTGF) knock out mice.

Journal of Histochemistry and Cytochemistry 2007; 55:1139-47,

64. E.J. [Kuiper, van Zijderveld R, Roestenberg P, Lyons KM, Goldschmeding R, Klaassen I, Van Noorden CJ, Schlingemann RO.](#)

Connective Tissue Growth Factor Is Necessary for Retinal Capillary Basal Lamina Thickening in Diabetic Mice.

J Histochem Cytochem. 2008;56:785-92. Epub 2008 May 12

if 2.7

63. P. [Borst, van de Wetering K, Schlingemann R.](#)

Does the absence of ABCC6 (Multidrug Resistance Protein 6) in patients with Pseudoxanthoma elasticum prevent the liver from providing sufficient vitamin K to the periphery?

Cell Cycle. 2008;7:1575-9. Epub 2008 Mar 31

if 5.4

62. [Santiago AR, Hughes JM, Kamphuis W, Schlingemann RO, Ambrósio AE.](#)

Diabetes changes ionotropic glutamate receptor subunit expression level in the human retina.

Brain Res. 2008; 1198:153-9

if 2.7

61. [Jaalouk DE, Ozawa MG, Sun J, Lahdenranta J, Schlingemann RO, Pasqualini R, Arap W.](#)

The original Pathologische Anatomie Leiden-Endothelium monoclonal antibody recognizes a vascular endothelial growth factor binding site within neuropilin-1.

Cancer Res. 2007; 67:9623-9.

if 7.9

60. [van Weel V, Seghers L, de Vries MR, Kuiper EJ, Schlingemann RO, Bajema IM, Lindeman JH, Delis-van Diemen PM, van Hinsbergh VW, van Bockel JH, Quax PH.](#)

Expression of vascular endothelial growth factor, stromal cell-derived factor-1, and CXCR4 in human limb muscle with acute and chronic ischemia.

Arterioscler Thromb Vasc Biol. 2007;27:1426-32. Epub 2007 Mar 15.

if 6.4

59. [Biallostowski C, van Velthoven ME, Michels RP, Schlingemann RO, Devries JH, Verbraak FD.](#)

Decreased optical coherence tomography-measured pericentral retinal thickness in patients with diabetes mellitus type 1 with minimal diabetic retinopathy.

British Journal of Ophthalmology 2007;91:1135-8. Epub 2007 Mar 23

if 2.9

58. [Schmidt-Erfurth UM, Richard G, Augustin A, Aylward WG, Bandello F, Corcostegui B, Cunha-Vaz J, Gaudric A, Leys A, Schlingemann R.O. ; on behalf of the European Society for Retina Specialists' Guidelines Committee \(EURETINA\).](#)

Guidance for the treatment of neovascular age-related macular degeneration.

Acta Ophthalmol Scand. 2007 Aug;85(5):486-94.

if 2.6

57. Richtlijn werkgroep diabetische retinopathie van het Nederlands Oogheelkundig Gezelschap en Orde van Medisch Specialisten. Richtlijn. Diabetische retinopathie. Screening, diagnostiek en behandeling. 2006; ISBN-10: 90-8523-125.6 --
56. [Missotten GS, Notting IC, R.O. Schlingemann, Zijlmans HJ, Lau C, Eilers PH, Keunen JE, Jager MJ.](#)
 Vascular endothelial growth factor a in eyes with uveal melanoma.
Archives of Ophthalmology 2006; 124:1428-34. **if 3.7**
55. M.E.J. van Velthoven, J.V. Ongkosuwito, F.D. Verbraak, **R.O. Schlingemann**, M.D. de Smet.
 Combined en-face optical coherence tomography and confocal ophthalmoscopy findings in active multifocal and serpiginous chorioretinitis
American Journal of Ophthalmology, 2006 May;141(5):972-5 **if 4.2**
54. M.E.J. van Velthoven, M.D. de Smet,, **R.O. Schlingemann**, M. Magnani., F.D. Verbraak.
 Added value of OCT in evaluating the presence of leakage in patients with age-related macular degeneration treated with PDT.
Graefes Arch Clin Exp Ophthalmol 2006; Sep;244(9):1119-23 **if 2.2**
53. F.D. Verbraak, **R.O. Schlingemann**, M.D. de Smet, J.F. Keunen.
 Single spot PDT in patients with Circumscribed Choroidal Haemangioma and near normal visual acuity.
Graefes Arch Clin Exp Ophthalmol. 2006 Sep;244(9):1178-82. **if 2.2**
52. M.E.J. van Velthoven, F.D. Verbraak, P.M. Garcia, **R.O. Schlingemann**, R.B. Rosen, M.D. de Smet.
 Evaluation of Central Serous Retinopathy with en-face Optical Coherence Tomography.
British Journal of Ophthalmology 2005;89, **if 2.9**
51. N. van Royen, S.H. Schirmer, B. Atasever, C.Y.H. Behrens, D. Ubbink, E.E. Buschmann, M. Voskuil, P. Bot, I. Hoefler, **R.O. Schlingemann**, B.J. Biemond, C. Bode, W. Schaper, J. Oskam, D.A. Legemate, J.J. Piek, I. Buschmann.
 The START-trial: a pilot study on stimulation of arteriogenesis using subcutaneous application of GM-CSF as a new treatment for peripheral vascular disease.
Circulation 2005; 112:1040-1046, **if**
- 14.7**
50. V. van Weel, M.M.L. Deckers, J.M. Grimbergen, K.J.M. van Leuven, J.W.H.P. Lardenoye, **R.O. Schlingemann**, G. Van Nieuw Amerongen, J.H. van Bockel, V.W.M. van Hinsbergh, P.H.A. Quax.
 Vascular endothelial growth factor improves ischemic skeletal muscle recovery by upregulation of myoglobin in vivo.
Circulation Research 2004; 95:58-66, **if 9.5**
49. I.M.M. Wakelkamp, H. Tan, P. Saeed, **R.O. Schlingemann**, F.D. Verbraak, M.D. de Smet, L.E.C. Blank, M.F. Prummel, W.M. Wiersinga.

- Is retrobulbar irradiation safe in the long run? The Amsterdam Graves' ophthalmopathy (GO) follow-up study.
Ophthalmology 2004; 111:1557-1562, **if 5.5**
48. J. Hughes, A. Brink, A.N. Witmer, M. Hanraads-de Riemer, I. Klaassen, **R.O. Schlingemann**.
 Vascular leukocyte adhesion molecules unaltered in the human retina in diabetes.
British Journal of Ophthalmology 2004; 88:566-572, **if 2.9**
47. E.J. Kuiper, A.N. Witmer, I. Klaassen, J. Hughes, M. Hanraads, J. Aten, R. Goldschmeding, **R.O. Schlingemann**.
 Differential expression of connective tissue growth factor in microglia and pericytes in the human diabetic retina.
British Journal of Ophthalmology 2004; 88: 1082-1087, **if 2.9**
46. W.G.M. Spliet, E. Aronica, M. Ramkema, A.N. Witmer, **R.O. Schlingemann**, V.J.M.B. de Jong, D. Troost.
 Immunohistochemical localization of vascular endothelial growth factor receptors 1, 2 and 3 in human spinal cord: altered expression in amyotrophic lateral sclerosis.
Neuropathology and Applied Neurobiology 2004; 30:351-359, **if 3.8**
45. P. Roestenberg, F.A. van Nieuwenhoven, L. Wieten, P. Boer, M.J.M. Diekman, A. Tiller, W.M. Wiersinga, N. Oliver, W. Usinger, S. Weitz, **R.O. Schlingemann**, R. Goldschmeding.
 Connective tissue growth factor (CTGF) plasma level is increased in type 1 diabetic patients with nephropathy.
Diabetes Care 2004; 27: 1164-1170, **if 8,1**
44. A.N. Witmer, B.C. van Blijswijk, C.J.F. van Noorden, G.F.J.M. Vrensen and **R.O. Schlingemann**.
 In vivo angiogenic phenotype of endothelial cells and pericytes induced by vascular endothelial growth factor-A.
Journal of Histochemistry and Cytochemistry 2004; 52:39-52, **if 2.7**
43. H.M. Verheul, E.E. Voest, **R.O. Schlingemann**.
 Are tumours angiogenesis-dependent? Invited review.
Journal of pathology 2004; 202:5-13, **if 4.9**
42. F.D. Verbraak, **R.O. Schlingemann**, J.E.E. Keunen and M.D. de Smet.
 Anatomical and functional success of a single treatment with photodynamic therapy using verteporfin in patients with longstanding circumscribed choroidal hemangioma.
Graefe's Archive for Clinical and Experimental Ophthalmology 2003;241:891-898, **if 2.2**
41. Russel S. et al. The Anecortave Acetate Clinical Study Group.
 Anecortave acetate as monotherapy for treatment of subfoveal neovascularisation in age-related macular degeneration (AMD): twelve-month clinical outcomes.
Ophthalmology 2003; 110:2372-2383, **if 5,5**
40. G.S.O.A. Missotten, H.M.H. Hurks, J.G. Journée-de Korver, D. de Wolff-Rouendaal, **R.O. Schlingemann**, J.E.E. Keunen and M.J. Jager.

Heat shock protein expression in the eye and in uveal melanoma.

Investigative Ophthalmology and Visual Science 2003; 44:3059-3065, **if 6.0**

39. D'Amico DJ et al. The Anecortave Acetate Clinical Study Group.

Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy.

Retina 2003;23:14-23, **if 2.8**

38. A.N. Witmer, H.G. Blaauwgeers, H.A. Weich, K. Alitalo, G.F.J.M. Vrensen and **R.O. Schlingemann.**

Altered Expression Patterns of VEGF Receptors in Human Diabetic Retina and in Experimental VEGF-Induced Retinopathy in Monkey.

Investigative Ophthalmology and Visual Science 2002; 43: 849-857, **if 3,6**

- 37 J. Dai, G.F.J.M. Vrensen, and **R.O. Schlingemann.**

Blood-brain barrier integrity is unaltered in human brain cortex with diabetes mellitus.

Brain Research 2002; 954:311-316, **if 2.7**

36. P. Hofman, H.G.T. Blaauwgeers, G.F.J.M. Vrensen, **R.O. Schlingemann.**

Role of VEGF-A in endothelial phenotypic shift in human diabetic retinopathy and VEGF-A induced retinopathy in monkeys.

Ophthalmic Research 2001; 33: 156-62, **if 1.6**

35. A. N. Witmer, B.C. van Blijswijk, P. Hofman, J. Dai, M.E. Kroon, T.A. Partanen, G.F.J.M. Vrensen and **R.O. Schlingemann.**

VEGFR-3 in adult angiogenesis.

Journal of Pathology 2001;195:490-497, **if 4.9**

34. P. Hofman, F. Van der Werf, G.F.J.M. Vrensen, H.G.T. Blaauwgeers and **R.O. Schlingemann.**

Capillaries in the optic nerve head lack blood-brain barrier characteristics.

Investigative Ophthalmology and Visual Science 2001; 42:895-901, **if 3.6**

33. A. N. Witmer, J. van den Born, G.F.J.M. Vrensen and **R.O. Schlingemann.**

Vascular localization of heparan sulphate proteoglycans in retinas of patients with diabetes mellitus and in VEGF-induced retinopathy using domain-specific antibodies.

Current Eye Research 2001; 22:190-7, **if 1.3**

32. P. Hofman, H.G.T. Blaauwgeers, M.J. Tolentino, A.P. Adamis, B. Nunes Cardozo, G.F.J.M.

Vrensen, **R.O. Schlingemann.**

Vascular hyperpermeability induced by VEGF-A in blood-brain barrier endothelium is associated with altered pinocytotic transport and not with formation of endothelial fenestrations.

- Current Eye Research* 2000; 21:637-45, **if 1.3**
31. C.G. Schalkwijk, N. Ligtvoet, H. Twaalfhoven, H.G.T. Blaauwgeers, **R. O. Schlingemann**, C.D.A. Stehouwer, V.W.M. van Hinsbergh.
- Immuno(histo)chemical detection of amadori-albumin and associations with markers of endothelial function in IDDM: production and characterization of an antibody against amadori-albumin.
- Diabetes* 1999; 48:2446-53, **if 8.84**
30. **R.O. Schlingemann**, P. Hofman, J. Klooster, H. Blaauwgeers, R. van der Gaag and G. Vrensen.
- Ciliary muscle capillaries have blood-tissue barrier characteristics.
- Experimental Eye Research* 1998; 66:747-754, **if 3.3**
29. **R.O. Schlingemann**, V.W.M. van Hinsbergh.
- Role of vascular permeability factor/ vascular endothelial growth factor in eye disease.
- British Journal of Ophthalmology* 1997, 81: 501-513, **if 2.9**
28. **R.O. Schlingemann**, P. Hofman, L. Andersson, D. Troost and R. van der Gaag.
- Vascular expression of endothelial antigen PAL-E indicates absence of blood-ocular barriers in the normal eye.
- Ophthalmic Research* 1997, 29:130-139, **if 1.6**
27. I. Mombaerts, **R.O. Schlingemann**, R. Goldschmeding and L. Koornneef.
- Are systemic corticosteroids useful in the management of orbital pseudotumors ?
- Ophthalmology* 1996; 103:521-528, **if 5.5**
26. **R.O. Schlingemann**, E. Oosterwijk, P. Wesseling, F.J.R. Rietveld and D.J. Ruiter.
- Aminopeptidase-A as constituent of the altered phenotype of activated pericytes in angiogenesis.
- Journal of Pathology* 1996; 179:436-442, **if 4.9**
25. I. Mombaerts, R. Goldschmeding, **R.O. Schlingemann** and L. Koornneef, .
- What is orbital pseudotumor ?
- Survey of Ophthalmology* 1996; 41:66-78, **if 3.2**
24. I. Mombaerts, **R.O.Schlingemann**, R. Goldschmeding, A. Noorduynd and L. Koornneef.
- The surgical management of lacrimal gland pseudotumors.
- Ophthalmology* 1996; 103:1619-27, **if 5.5**
23. **R.O. Schlingemann**, M. Bruinenberg, P. Wertheim-van Dillen and E. Feron.
- 20 years delay in fellow eye involvement in HSV type 2-associated bilateral acute retinal necrosis syndrome.

- American Journal of Ophthalmology* 1996; 122:891-2, **if 4.2**
22. **R.O. Schlingemann**, P.M.E. Wertheim-van Dillen, A. Kijlstra, C. Meenken, P.J.M. Bos and E.Feron.
Bilateral CMV retinitis in a patient with systemic lupus erythematosus.
British Journal of Ophthalmology 1996; 80; 1109-1110, **if 2.9**
21. I. Mombaerts, **R.O. Schlingemann**, R. Goldschmeding and L. Koornneef.
Idiopathic granulomatous orbital inflammations.
Ophthalmology 1996; 103:2135-4, **if 5.5**
20. P. Wesseling, **R.O. Schlingemann**, F.J.R. Rietveld, P.C. Burger and D.J. Ruiter.
Early and extensive contribution of pericytes/vascular smooth muscle cells to microvascular proliferation in glioblastoma multiforme.
Journal of Neuropathology and Experimental Neurology 1995; 54:304-310, **if 4.3**
19. D.J. Ruiter, **R.O. Schlingemann**, F.J.R. Rietveld, and R.M.W. de Waal.
Monoclonal antibody defined human endothelial antigens as vascular markers.
Journal of Investigative Dermatology 1989; 93:25S-32S, **if 6.3**
18. R. Verheijen, H.J.H. Kuijpers, **R.O. Schlingemann**, A.L.M. Boehmer, R. van Driel, G.J. Brakenhoff and F.C.S.Ramaekers.
Ki-67 detects a nuclear matrix-associated proliferation-related antigen. I. Species distribution and intracellular localization during interphase.
Journal of Cell Science 1989; 92:123-130, **if 6.1**
17. S.R. Serawar, **R.O. Schlingemann**, A. Kelsey, S. Fleming and S. Kumar.
A monoclonal antibody stains blastemal but not tubular components of Wilms' tumour.
Journal of Pathology 1988; 156:319-324, **if 4.9**
16. E.C. Hagen, C. Vennegoor, **R.O. Schlingemann**, E.A. van de Velde and D.J. Ruiter.
Correlation of histopathological characteristics with staining patterns in human melanoma assessed by (monoclonal) antibodies reactive on paraffin sections.
Histopathology 1986; 10:689-700, **if 3.1**

-National (refereed) journals

15. S.C. Walland, **R.O. Schlingemann**, Redactiecommissie Gebu.

Nieuwe geneesmiddelen voor maculadegeneratie.

Gebu 2008; 42:31-36

14. [Schlingemann RO, van der Meulen JJ, Nieuwendaal CP.](#)

The practice guideline 'The red eye' (first revision) of the Dutch College of General Practitioners; a response from the perspective of the ophthalmologist

Nederlands Tijdschrift voor Geneeskunde 2007;151:1219-21

13. W. hartstra, F.Holleman, J.B. Hoekstra, **R.O. Schlingemann**

Screening op diabetische retinopathie.

Nederlands Tijdschrift voor Geneeskunde 2007;151:228-233

12. B.J. van den Born, **R.O. Schlingemann**, J.B. Hoekstra, G.A. van Montfrans

De waarde van routinematig onderzoek van de fundus bij patiënten met hypertensie.

Nederlands Tijdschrift voor Geneeskunde 2004; 148: 464-468

11. **R.O. Schlingemann.**

Duisternis leidt mogelijk tot verergering van diabetische retinopathie. Referaat.

Nederlands Tijdschrift voor Geneeskunde 2003; 147(4):179-180

10. Marinkovic, J.J.B van Lanschaot, **R.O. Schlingemann**, M.D. de Smet and P. Saeed

Oogklachten wijzend op een tujor elders in het lichaam

Nederlands Tijdschrift voor Geneeskunde 2002;146(50):2393-2396

9 **R.O. Schlingemann** and C.P. Nieuwendaal.

Oogproblemen door contactlenzen; een advies van de Gezondheidsraad.

Nederlands Tijdschrift voor Geneeskunde 2002; 146(35):1616-1620

8. **R.O. Schlingemann**, H.M.A. Brink and H.J.M. Volker-Dieben.

De standaard 'Refractieafwijkingen' van het Nederlands Huisartsen Genootschap; reactie vanuit de oogheelkunde.

Nederlands Tijdschrift voor Geneeskunde 2002;146(38):1771-1774

7. **R.O. Schlingemann.**

Vernauwde retinale arteriolen zijn een onafhankelijke voorspeller van diabetes mellitus type 2. Referaat.

Nederlands Tijdschrift voor Geneeskunde 2002; 146(40):1909

6. J.W.M. Brans, M. Aramideh, **R.O. Schlingemann**, V.M.L.H. Oen, J.D. Speelman en B.W.

Ongerboer de Visser.

Protectieve ptosis: een nieuwe klinische toepassing van botuline.

Nederlands Tijdschrift voor Geneeskunde 1996; 140:1031-1033

5. **R.O. Schlingemann.**

Uitschakeling van bloedvatvorming in tumorweefsel: nieuwe strategie voor kankertherapie?

Tijdschrift Kanker 1993; 17:22-24

-Books, or contributions to books

4. D.J. Ruiter, **R.O. Schlingemann**, J.R. Westphal, M. Denijn, F.J.R. Rietveld, and R.M.W. deWaal.
Angiogenesis in wound healing and tumor metastasis.
Behring Institute Mitteilungen 1993; 92:258-272
3. **R.O. Schlingemann**.
Vascular markers in tumor biology.
Thesis 1990; Nijmegen University, Nijmegen, The Netherlands.
2. **R.O. Schlingemann**, G.Th.A.M. Bots, S.G. van Duinen and D.J. Ruiter.
Differential expression of endothelium-specific antigen PAL-E in vasculature of brain tumors and preexistent brain capillaries.
In: Blood-Brain Transfer; Annals of the New York Academy of Sciences 1988; Vol 465:111-114;
Editor: F.Strand
1. C.J. Schep, N.J. Mars and **R.O. Schlingemann**.
Een medisch expert systeem gebaseerd op EMYCIN.(A medical expert system based on EMYCIN).
Published by the Department of Information Science, Leiden, 1984. ISBN 9070647028